ICER says it's fair for Bio­Marin and CSL to price in­com­ing he­mo­phil­ia gene ther­a­pies at $2M-$3M

Get ready for mil­lion-plus-dol­lar gene ther­a­pies to be­come the norm rather than the ex­cep­tion, and in some cas­es, the Boston-based drug pric­ing watch­dog ICER is com­ing on board.

The non­prof­it ICER (In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view) on Wednes­day un­veiled a new re­port find­ing that CSL Behring’s po­ten­tial gene ther­a­py etranaco­gene deza­parvovec for he­mo­phil­ia B, which is due for an FDA ap­proval de­ci­sion by the end of this month, could be fair­ly priced at around $3 mil­lion. ICER al­so up­dat­ed its pre­vi­ous as­sess­ment of Bio­Marin’s EU-au­tho­rized he­mo­phil­ia A gene ther­a­py Roc­ta­vian, which ICER said could be fair­ly priced at about $2 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.